Sanofi, GSK say Covid booster shot works better against Omicron variant

The companies point to the risk of new variants and waning immunity that could lead to an increase in demand for additional booster shots in some populations.

Sanofi and GSK Plc, the pharma giants that fell behind in the race to develop a Covid-19 shot, said their experimental booster vaccine delivers a more powerful immune response against coronavirus variants than their competitors’. 
 

The shot raised antibody levels in adults already inoculated with messenger RNA vaccines more than the additional doses from Pfizer Inc. and BioNTech SE, and demonstrated potential to protect against variants including omicron, GSK and Sanofi said in a statement Monday, citing data from two trials. 

Shares in Sanofi and GSK were little changed in early trading. 

The companies point to the risk of new